Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases

Research output: Contribution to journalReview articlepeer-review


Despite the evolving therapeutic armamentarium, the treatment of IBD patients remains challenging and many patients fail to respond to biologic agents. With the limited yield of clinical factors to predict the outcome of biologic treatments, studies have focused on identifying genetic alterations and circulating or tissue biomarkers to identify patients who are likely to respond to therapy. In this review, we examine the current knowledge and status of genetic, expression biomarkers, and microbiome predictors. The search for genetic predictors has yielded many genetic loci variants, but few were reproducible. Expression studies of putative biomarkers show promising results, especially with TREM1, oncostatin M and TNF biomarkers, but confirmatory studies are warranted. Finally, the microbiome is emerging as an important player with specific taxa and functional pathways differentially abundant and enriched in responders versus non-responders to certain biologics. Integrating different factors into a robust predictive model, which is both reproducible, accurate and affordable, remains the main challenge before these individualized strategies can reach clinical use.

Original languageEnglish
Pages (from-to)132-140
Number of pages9
JournalCurrent Opinion in Pharmacology
StatePublished - Dec 2020


Dive into the research topics of 'Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this